Article and Video CATEGORIES
Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) in a study, specifically for patients with PD-L1. What are the implications of multiple agents with similar mechanisms of action in the same clinical settings?
[powerpress]
Please feel free to offer comments and raise questions in our Discussion Forums.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi Ascardino, Welcome to Grace. I'm so sorry to hear of your situation. While we don't have specific info or expertise on ovarian cancer, I did some searching for information. It...
Hello Janine,
Thank you for sharing this valuable leukemia playlist—building a reliable knowledge base like this truly makes a difference for everyone navigating such a challenging journey. I appreciate the open...
I don't know what to do. No insurance